Latest News
Palantir has investors abuzz.
Via The Motley Fool · August 12, 2026
The memory maker has far outperformed many of its semiconductor peers throughout 2026, but its rally could just be getting started.
Via The Motley Fool · August 12, 2026
After a strong multiyear run, the S&P 500 now trades at a lofty valuation.
Via The Motley Fool · August 12, 2026
Paysign Inc (NASDAQ:PAYS) Shows Accelerating Growth and Improving Fundamentalschartmill.com
Via Chartmill · August 12, 2026
Lam Research (NASDAQ:LRCX): A Quality Compounder for Long-Term Investorschartmill.com
Via Chartmill · August 12, 2026
As hyperscalers invest hundreds of trillions in AI infrastructure in the coming years, these two companies are top beneficiaries.
Via The Motley Fool · August 12, 2026
Despite strong fundamentals, these financial stocks have underperformed the market in 2026.
Via The Motley Fool · August 12, 2026
The robotics boom could benefit far more than Tesla.
Via The Motley Fool · August 12, 2026
Another $42.5 billion in potential selling pressure takes effect on Aug. 21.
Via The Motley Fool · August 12, 2026
Abel is making his mark on the company, but he's not veering too far away from Buffett.
Via The Motley Fool · August 12, 2026
Buffett is a big fan of low-cost index funds for everyday investors.
Via The Motley Fool · August 12, 2026
SpaceX stock could more than double in the next year as its booming artificial intelligence business continues to grow.
Via The Motley Fool · August 12, 2026
It's not complicated, but it's not exactly easy to do, either.
Via The Motley Fool · August 12, 2026
C.H. Robinson Worldwide (NASDAQ:CHRW) executives said the company plans to appeal a large jury verdict tied to a fatal accident in Dallas, while maintaining that the outcome will not alter its operating strategy, capital allocation priorities or outlook for its brokerage business.
Speaking at the C
Via MarketBeat · August 12, 2026
K+S Aktiengesellschaft (ETR:SDF) raised its full-year 2026 outlook after second-quarter EBITDA rose significantly from the prior-year period, supported by higher average selling prices, stronger volumes and cost discipline.
CEO Christian H. Meyer said second-quarter EBITDA reached approximately €17
Via MarketBeat · August 12, 2026
CLS (LON:CLI) reported lower first-half earnings as property disposals, tenant departures and valuation declines weighed on results, while the office investor continued its program of asset sales, debt reduction and refinancing.
Chief Executive Fredrik Widlund said the company faces “near-term earn
Via MarketBeat · August 12, 2026
Evoke (LON:EVOK) reported stable first-half revenue and lower adjusted EBITDA as increased gaming duties, particularly in the U.K., added a £46 million year-on-year cost headwind. Management said mitigation efforts, including more efficient marketing, cost savings and retail estate changes, offset m
Via MarketBeat · August 12, 2026
TripleLift appoints Dave Simon as Chief Revenue Officer to lead its global revenue organization and support the company's next phase of commercial growth.
Via Talk Markets · August 12, 2026
https://sites.google.com/view/investinoutdoorledcurtainwalls/Looking to install Outdoor LED Curtain Walls Lebanon? Simply contact Electro Media Internation
Via Talk Markets · August 12, 2026
SoundHound's conversational artificial intelligence software is in high demand.
Via The Motley Fool · August 12, 2026
The gaming world is buzzing about Onimusha: Way of the Sword, with its realistic swordplay and highly detailed combat animation becoming a major talking po
Via Talk Markets · August 12, 2026
The cost of Amazon's AI pivot may be weighing on the stock.
Via The Motley Fool · August 12, 2026
The chip and software giant's reported profits more than doubled over the past year -- which happens to be how this gap closed both times before.
Via The Motley Fool · August 12, 2026
Lip colour can naturally vary from person to person. However, factors such as genetics, sun exposure, hormonal changes, smoking, dehydration, certain cosme
Via Talk Markets · August 12, 2026
When it comes to antiretroviral therapy, access to appropriately formulated medicines is an important part of HIV care. Efamax HIV/ARV Tablets Manufacturer
Via Talk Markets · August 12, 2026
